Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 45Cyclophosphamide 43Specimen Handling 41Cytarabine 39fludarabine 31Biopsy 30Azacitidine 24Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 15Vincristine 15Dexamethasone 14Daunorubicin 14ibrutinib 13Prednisone 13Magnetic Resonance Spectroscopy 13Whole-Body Irradiation 12Injections 12obinutuzumab 11merphos 11Mercaptopurine 11Calcium Dobesilate 11Mycophenolic Acid 10Filgrastim 10Doxorubicin 10X-Rays 9Tacrolimus 9Leucovorin 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vorinostat × Other hematologic neoplasm × 30 days × Clear all
NCT05848687 2026-06-03

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Stanford University

Phase 1/2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡